Advertisement
Screener

INFUSYSTEM HOLDINGS, INC (INFU) Proceeds from (Payments for) Other Financing Activities

2.5 / 5 stars · 59/119 Roast Me

INFUSYSTEM HOLDINGS, INC Proceeds from (Payments for) Other Financing Activities

INFUSYSTEM HOLDINGS, INC (INFU) reported Proceeds from (Payments for) Other Financing Activities of $13.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities · last filed 2026-08-04

  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for the quarter ending 2026-06-30 was $7.50M, a 44.36% decline year-over-year.
  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for the quarter ending 2026-03-31 was $6.14M, a 68.05% decline year-over-year.
  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for the quarter ending 2025-12-31 was $6.72M, a 41.87% decline year-over-year.
  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for the quarter ending 2025-09-30 was $8.79M, a 17.73% increase year-over-year.
  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for fiscal 2025 was $48.23M, a 5.06% decline from fiscal 2024.
  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for fiscal 2024 was $50.80M, a 1.46% decline from fiscal 2023.
  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for fiscal 2023 was $51.55M, a 22.68% increase from fiscal 2022.
  • INFUSYSTEM HOLDINGS, INC proceeds from (payments for) other financing activities for fiscal 2022 was $42.02M, a 44.85% decline from fiscal 2021.
Period endProceeds from (Payments for) Other Financing Activities 3 monthProceeds from (Payments for) Other Financing Activities 6 monthProceeds from (Payments for) Other Financing Activities 9 monthProceeds from (Payments for) Other Financing Activities 12 month
2026-06-30$7.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$13.65M
10-Q · filed 2026-08-04
$20.37M
derived: sum of 3 quarters · filed 2026-08-04
$29.16M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$6.14M
10-Q · filed 2026-05-08
$12.87M
derived: sum of 2 quarters · filed 2026-05-08
$21.65M
derived: sum of 3 quarters · filed 2026-05-08
$35.14M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$6.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$15.51M
derived: sum of 2 quarters · filed 2026-02-27
$29.00M
derived: sum of 3 quarters · filed 2026-08-04
$48.23M
10-K · filed 2026-02-27
2025-09-30$8.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$22.27M
derived: sum of 2 quarters · filed 2026-08-04
$41.50M
10-Q · filed 2025-11-04
$53.07M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$13.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$32.72M
10-Q · filed 2026-08-04
$44.28M
derived: sum of 3 quarters · filed 2026-08-04
$51.75M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$19.23M
10-Q · filed 2026-05-08
$30.80M
derived: sum of 2 quarters · filed 2026-05-08
$38.26M
derived: sum of 3 quarters · filed 2026-05-08
$53.96M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$11.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$19.03M
derived: sum of 2 quarters · filed 2026-02-27
$34.73M
derived: sum of 3 quarters · filed 2026-02-27
$50.80M
10-K · filed 2026-02-27
2024-09-30$7.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$23.16M
derived: sum of 2 quarters · filed 2025-11-04
$39.23M
10-Q · filed 2025-11-04
$47.99M
derived: sum of 4 quarters · filed 2025-11-04
2024-06-30$15.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$31.77M
10-Q · filed 2025-08-05
$40.53M
derived: sum of 3 quarters · filed 2025-08-05
$50.74M
derived: sum of 4 quarters · filed 2025-08-05
2024-03-31$16.07M
10-Q · filed 2025-05-08
$24.83M
derived: sum of 2 quarters · filed 2025-05-08
$35.04M
derived: sum of 3 quarters · filed 2025-05-08
$50.73M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31$8.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$18.97M
derived: sum of 2 quarters · filed 2025-03-11
$34.66M
derived: sum of 3 quarters · filed 2025-03-11
$51.55M
10-K · filed 2025-03-11
2023-09-30$10.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
$25.89M
derived: sum of 2 quarters · filed 2024-11-08
$42.79M
10-Q · filed 2024-11-08
$52.41M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30$15.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
$32.59M
10-Q · filed 2024-08-09
$42.21M
derived: sum of 3 quarters · filed 2024-08-09
$53.39M
derived: sum of 4 quarters · filed 2024-08-09
2023-03-31$16.89M
10-Q · filed 2024-05-09
$26.52M
derived: sum of 2 quarters · filed 2024-05-09
$37.70M
derived: sum of 3 quarters · filed 2024-05-09
$46.39M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$9.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10
$20.80M
derived: sum of 2 quarters · filed 2024-04-10
$29.49M
derived: sum of 3 quarters · filed 2024-04-10
$42.02M
10-K · filed 2024-04-10
2022-09-30$11.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$19.87M
derived: sum of 2 quarters · filed 2023-11-09
$32.40M
10-Q · filed 2023-11-09
$46.94M
derived: sum of 4 quarters · filed 2024-04-10
2022-06-30$8.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$21.22M
10-Q · filed 2023-08-09
$35.76M
derived: sum of 3 quarters · filed 2024-04-10
$49.50M
derived: sum of 4 quarters · filed 2024-04-10
2022-03-31$12.53M
10-Q · filed 2023-05-09
$27.07M
derived: sum of 2 quarters · filed 2024-04-10
$40.81M
derived: sum of 3 quarters · filed 2024-04-10
$54.72M
derived: sum of 4 quarters · filed 2024-04-10
2021-12-31$14.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10
$28.28M
derived: sum of 2 quarters · filed 2024-04-10
$42.19M
derived: sum of 3 quarters · filed 2024-04-10
$76.19M
10-K · filed 2024-04-10
2021-09-30$13.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$27.65M
derived: sum of 2 quarters · filed 2022-11-08
$61.65M
10-Q · filed 2022-11-08
$67.38M
derived: sum of 4 quarters · filed 2023-03-16
2021-06-30$13.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$47.91M
10-Q · filed 2022-08-04
$53.64M
derived: sum of 3 quarters · filed 2023-03-16
$59.24M
derived: sum of 4 quarters · filed 2023-03-16
2021-03-31$34.00M
10-Q · filed 2022-05-05
$39.73M
derived: sum of 2 quarters · filed 2023-03-16
$45.33M
derived: sum of 3 quarters · filed 2023-03-16
$61.12M
derived: sum of 4 quarters · filed 2023-03-16
2020-12-31$5.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
$11.33M
derived: sum of 2 quarters · filed 2023-03-16
$27.12M
derived: sum of 3 quarters · filed 2023-03-16
$37.59M
10-K · filed 2023-03-16
2020-09-30$5.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$21.39M
derived: sum of 2 quarters · filed 2021-11-15
$31.86M
10-Q · filed 2021-11-15
$33.84M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$15.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$26.26M
10-Q · filed 2021-08-12
$28.23M
derived: sum of 3 quarters · filed 2021-08-12
$33.67M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$10.47M
10-Q · filed 2021-05-10
$12.44M
derived: sum of 2 quarters · filed 2021-05-10
$17.88M
derived: sum of 3 quarters · filed 2021-05-10
2019-12-31$1.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22
$7.41M
derived: sum of 2 quarters · filed 2021-03-22
$9.44M
10-K · filed 2021-03-22
2019-09-30$5.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13
$7.46M
10-Q · filed 2020-11-13
2019-06-30$2.02M
10-Q · filed 2020-08-14
2018-12-31$1.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30
$11.16M
10-K · filed 2020-03-30
2018-09-30$9.66M
10-Q · filed 2019-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
PRO DEX INC (PDEX)United States$0.234B13.64
Cytosorbents Corp (CTSO)United States$0.274B-1.29
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Neuronetics, Inc. (STIM)United States$0.216B-3.25
Mobia Medical, Inc. (MOBI)United States$0.293B
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
Profound Medical Corp. (PROF)$0.206B-7.37